Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1

European Heart Journal - Cardiovascular Pharmacotherapy, Volume 5, Issue 2, April 2019, Pages 64–69

Dr Baker and co-workers from the USA compared the effectiveness and safety of standard dose rivaroxaban (20 mg o.d.) and warfarin in non-valvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2-VASc score of 1. The authors used US Truven MarketScan claims from November 2011 to December 2016 for anticoagulant-naïve NVAF patients with a single non-sex-related stroke risk factor assigned 1 point in the CHA2DS2-VASc score and concluded that rivaroxaban may lower the rate of stroke or systemic embolism compared with warfarin in NVAF patients with a non-sex-related CHA2DS2-VASc score of 1 without impacting major bleeding. The treatment threshold in these patients has previously been discussed in our journal

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.